<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39408840</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>16</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>19</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>19</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>29</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>SARS-CoV-2-Specific T-Cell as a Potent Therapeutic Strategy against Immune Evasion of Emerging COVID-19 Variants.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">10512</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms251910512</ELocationID><Abstract><AbstractText>Despite advances in vaccination and therapies for coronavirus disease, challenges remain due to reduced antibody longevity and the emergence of virulent variants like Omicron (BA.1) and its subvariants (BA.1.1, BA.2, BA.3, and BA.5). This study explored the potential of adoptive immunotherapy and harnessing the protective abilities using virus-specific T cells (VSTs). Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) VSTs were generated by stimulating donor-derived peripheral blood mononuclear cells with spike, nucleocapsid, and membrane protein peptide mixtures. Phenotypic characterization, including T-cell receptor (TCR) vβ and pentamer analyses, was performed on the ex vivo-expanded cells. We infected human leukocyte antigen (HLA)-partially matched human Calu-3 cells with various authentic SARS-CoV-2 strains in a Biosafety Level 3 facility and co-cultured them with VSTs. VSTs exhibited a diverse TCR vβ repertoire, confirming their ability to target a broad range of SARS-CoV-2 antigens from both the ancestral and mutant strains, including Omicron BA.1 and BA.5. These ex vivo-expanded cells exhibited robust cytotoxicity and low alloreactivity against HLA-partially matched SARS-CoV-2-infected cells. Their cytotoxic effects were consistent across variants, targeting conserved spike and nucleocapsid epitopes. Our findings suggest that third-party partial HLA-matching VSTs could counter immune-escape mechanisms posed by emerging variants of concern.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Im</LastName><ForeName>Keon-Il</ForeName><Initials>KI</Initials><Identifier Source="ORCID">0000-0003-2811-9815</Identifier><AffiliationInfo><Affiliation>Institute for Translational Research and Molecular Imaging, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research and Development Division, LucasBio Co., Ltd., Seoul 06591, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Nayoun</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0001-8317-2921</Identifier><AffiliationInfo><Affiliation>Institute for Translational Research and Molecular Imaging, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research and Development Division, LucasBio Co., Ltd., Seoul 06591, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Junseok</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-4591-4693</Identifier><AffiliationInfo><Affiliation>Institute for Translational Research and Molecular Imaging, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oh</LastName><ForeName>Ui-Hyeon</ForeName><Initials>UH</Initials><AffiliationInfo><Affiliation>Research and Development Division, LucasBio Co., Ltd., Seoul 06591, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Hye-Won</ForeName><Initials>HW</Initials><AffiliationInfo><Affiliation>Research and Development Division, LucasBio Co., Ltd., Seoul 06591, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Dong-Gun</ForeName><Initials>DG</Initials><Identifier Source="ORCID">0000-0003-4655-0641</Identifier><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Vaccine Bio Research Institute, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Min</LastName><ForeName>Gi-June</ForeName><Initials>GJ</Initials><Identifier Source="ORCID">0000-0001-7636-4693</Identifier><AffiliationInfo><Affiliation>Institute for Translational Research and Molecular Imaging, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Hematology, Seoul St. Mary's Hematology Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Raeseok</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-1168-3666</Identifier><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Vaccine Bio Research Institute, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Jinah</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-7557-0265</Identifier><AffiliationInfo><Affiliation>Zoonotic Virus Laboratory, Institut Pasteur Korea, Seongnam 13488, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Seungtaek</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Zoonotic Virus Laboratory, Institut Pasteur Korea, Seongnam 13488, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cho</LastName><ForeName>Seok-Goo</ForeName><Initials>SG</Initials><Identifier Source="ORCID">0000-0002-5429-4839</Identifier><AffiliationInfo><Affiliation>Institute for Translational Research and Molecular Imaging, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research and Development Division, LucasBio Co., Ltd., Seoul 06591, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Hematology, Seoul St. Mary's Hematology Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>HI23C015100</GrantID><Agency>Ministry of Health and Welfare, Republic of Korea</Agency><Country /></Grant><Grant><GrantID>NRF-2023M3A9G6057281 and NRF-2022M3A9J1081343</GrantID><Agency>National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT)</Agency><Country /></Grant><Grant><GrantID>HI22C131400</GrantID><Agency>a grant of the Korea Health Technology R&amp;D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health &amp; Welfare, Republic of Korea</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000657845">spike protein, SARS-CoV-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018984">Epitopes, T-Lymphocyte</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057131" MajorTopicYN="Y">Immune Evasion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="Y">Spike Glycoprotein, Coronavirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013601" MajorTopicYN="N">T-Lymphocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016219" MajorTopicYN="N">Immunotherapy, Adoptive</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018984" MajorTopicYN="N">Epitopes, T-Lymphocyte</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007963" MajorTopicYN="N">Leukocytes, Mononuclear</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">coronavirus disease</Keyword><Keyword MajorTopicYN="N">immunotherapy</Keyword><Keyword MajorTopicYN="N">severe acute respiratory syndrome coronavirus 2</Keyword><Keyword MajorTopicYN="N">viral immunity</Keyword><Keyword MajorTopicYN="N">virus-specific T cells</Keyword></KeywordList><CoiStatement>Keon-Il Im, Nayoun Kim, Ui-Hyeon Oh, and Hye-Won Lee are employees and Seok-Goo Cho is the CEO of LucasBio, which develops products relevant to the subject matter discussed in this manuscript. The authors declare that this affiliation did not influence the design, execution, or interpretation of the research findings presented in this study. We have complied with the journal’s policy on competing interests, and all authors have disclosed any financial or personal relationships that could be perceived as potentially influencing the work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>9</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>10</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>10</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>1</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39408840</ArticleId><ArticleId IdType="pmc">PMC11477143</ArticleId><ArticleId IdType="doi">10.3390/ijms251910512</ArticleId><ArticleId IdType="pii">ijms251910512</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rydyznski Moderbacher C., Ramirez S.I., Dan J.M., Grifoni A., Hastie K.M., Weiskopf D., Belanger S., Abbott R.K., Kim C., Choi J., et al. Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. Cell. 2020;183:996–1012.e19. doi: 10.1016/j.cell.2020.09.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.09.038</ArticleId><ArticleId IdType="pmc">PMC7494270</ArticleId><ArticleId IdType="pubmed">33010815</ArticleId></ArticleIdList></Reference><Reference><Citation>Lafon E., Diem G., Witting C., Zaderer V., Bellmann-Weiler R.M., Reindl M., Bauer A., Griesmacher A., Fux V., Hoermann G., et al. Potent SARS-CoV-2-specific T cell immunity and low anaphylatoxin levels correlate with mild disease progression in COVID-19 patients. Front. Immunol. 2021;12:684014. doi: 10.3389/fimmu.2021.684014.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.684014</ArticleId><ArticleId IdType="pmc">PMC8237940</ArticleId><ArticleId IdType="pubmed">34194438</ArticleId></ArticleIdList></Reference><Reference><Citation>Jo N., Zhang R., Ueno H., Yamamoto T., Weiskopf D., Nagao M., Yamanaka S., Halmazaki Y. Aging and CMV infection affect pre-existing SARS-CoV-2-reactive CD8+ T cells in unexposed individuals. Front. Aging. 2021;2:719342. doi: 10.3389/fragi.2021.719342.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fragi.2021.719342</ArticleId><ArticleId IdType="pmc">PMC9261342</ArticleId><ArticleId IdType="pubmed">35822004</ArticleId></ArticleIdList></Reference><Reference><Citation>Bange E.M., Han N.A., Wileyto P., Kim J.Y., Gouma S., Robinson J., Greenplate A.R., Hwee M.A., Porterfield F., Owoyemi O., et al. CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer. Nat. Med. 2021;27:1280–1289. doi: 10.1038/s41591-021-01386-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01386-7</ArticleId><ArticleId IdType="pmc">PMC8291091</ArticleId><ArticleId IdType="pubmed">34017137</ArticleId></ArticleIdList></Reference><Reference><Citation>Toniutto P., Falleti E., Cmet S., Cussigh A., Veneto L., Bitetto D., Fornasiere E., Fumolo E., Fabris C., Sartor A., et al. Past COVID-19 and immunosuppressive regimens affect the long-term response to anti-SARS-CoV-2 vaccination in liver transplant recipients. J. Hepatol. 2022;77:152–162. doi: 10.1016/j.jhep.2022.02.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2022.02.015</ArticleId><ArticleId IdType="pmc">PMC8908852</ArticleId><ArticleId IdType="pubmed">35283215</ArticleId></ArticleIdList></Reference><Reference><Citation>Seow J., Graham C., Merrick B., Acors S., Pickering S., Steel K.J.A., Hemmings O., O’bYrne A., Kouphou N., Galao R.P., et al. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. Nat. Microbiol. 2020;5:1598–1607. doi: 10.1038/s41564-020-00813-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-020-00813-8</ArticleId><ArticleId IdType="pmc">PMC7610833</ArticleId><ArticleId IdType="pubmed">33106674</ArticleId></ArticleIdList></Reference><Reference><Citation>Galmiche S., Luong Nguyen L.B., Tartour E., de Lamballerie X., Wittkop L., Loubet P., Launay O. Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: A systematic review. Clin. Microbiol. Infect. 2022;28:163–177. doi: 10.1016/j.cmi.2021.09.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2021.09.036</ArticleId><ArticleId IdType="pmc">PMC8595936</ArticleId><ArticleId IdType="pubmed">35020589</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Beltran W.F., Lam E.C., St Denis K., Nitido A.D., Garcia Z.H., Hauser B.M., Feldman J., Pavlovic M.N., Gregory D.J., Poznansky M.C., et al. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell. 2021;184:2372–2383.e9. doi: 10.1016/j.cell.2021.03.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.03.013</ArticleId><ArticleId IdType="pmc">PMC7953441</ArticleId><ArticleId IdType="pubmed">33743213</ArticleId></ArticleIdList></Reference><Reference><Citation>Jordan S.C., Shin B.H., Gadsden T.M., Chu M., Petrosyan A., Le C.N., Zabner R., Oft J., Pedraza I., Cheng S., et al. T cell immune responses to SARS-CoV-2 and variants of concern (Alpha and Delta) in infected and vaccinated individuals. Cell Mol. Immunol. 2021;18:2554–2556. doi: 10.1038/s41423-021-00767-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-021-00767-9</ArticleId><ArticleId IdType="pmc">PMC8443898</ArticleId><ArticleId IdType="pubmed">34531555</ArticleId></ArticleIdList></Reference><Reference><Citation>Naranbhai V., Nathan A., Kaseke C., Berrios C., Khatri A., Choi S., Getz M.A., Tano-Menka R., Ofoman O., Gayton A., et al. T cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all individuals. Cell. 2022;185:1259. doi: 10.1016/j.cell.2022.03.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.03.022</ArticleId><ArticleId IdType="pmc">PMC8969090</ArticleId><ArticleId IdType="pubmed">35364034</ArticleId></ArticleIdList></Reference><Reference><Citation>Harvey W.T., Carabelli A.M., Jackson B., Gupta R.K., Thomson E.C., Harrison E.M., Ludden C., Reeve R., Rambaut A., Consortium C.-G.U., et al. SARS-CoV-2 variants, spike mutations and immune escape. Nat. Rev. Microbiol. 2021;19:409–424. doi: 10.1038/s41579-021-00573-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-021-00573-0</ArticleId><ArticleId IdType="pmc">PMC8167834</ArticleId><ArticleId IdType="pubmed">34075212</ArticleId></ArticleIdList></Reference><Reference><Citation>Kotaki R., Moriyama S., Oishi S., Onodera T., Adachi Y., Sasaki E., Ishino K., Morikawa M., Takei H., Takahashi H., et al. Repeated Omicron exposures redirect SARS-CoV-2-specific memory B cell evolution toward the latest variants. Sci. Transl. Med. 2024;16:eadp9927. doi: 10.1126/scitranslmed.adp9927.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.adp9927</ArticleId><ArticleId IdType="pubmed">39167666</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization  Therapeutics and COVID-19: Living Guideline. 13 January 2023.  [(accessed on 26 October 2023)].  Available online:  https://www.who.int/publications/i/item/WHO-2019-nCoV-therapeutics-2023.2.</Citation></Reference><Reference><Citation>RECOVERY Collaborative Group. Horby P., Lim W.S., Emberson J.R., Mafham M., Bell J.L., Linsell L., Staplin N., Brightling C., Ustianowski A., et al. Dexamethasone in hospitalized patients with COVID-19. N. Engl. J. Med. 2021;384:693–704. doi: 10.1056/nejmoa2021436.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejmoa2021436</ArticleId><ArticleId IdType="pmc">PMC7383595</ArticleId><ArticleId IdType="pubmed">32678530</ArticleId></ArticleIdList></Reference><Reference><Citation>Beigel J.H., Tomashek K.M., Dodd L.E., Mehta A.K., Zingman B.S., Kalil A.C., Hohmann E., Chu H.Y., Luetkemeyer A., Kline S., et al. Remdesivir for the treatment of COVID-19—Final report. N. Engl. J. Med. 2020;383:1813–1826. doi: 10.1056/NEJMoa2007764.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2007764</ArticleId><ArticleId IdType="pmc">PMC7262788</ArticleId><ArticleId IdType="pubmed">32445440</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Z., Gao W., Bao H., Feng H., Mei S., Chen P., Gao Y., Cui Z., Zhang Q., Meng X., et al. VV116 versus nirmatrelvir-ritonavir for oral treatment of COVID-19. N. Engl. J. Med. 2023;388:406–417. doi: 10.1056/NEJMoa2208822.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2208822</ArticleId><ArticleId IdType="pmc">PMC9812289</ArticleId><ArticleId IdType="pubmed">36577095</ArticleId></ArticleIdList></Reference><Reference><Citation>Jayk Bernal A., Gomes da Silva M.M., Musungaie D.B., Kovalchuk E., Gonzalez A., Delos Reyes V., Martín-Quirós A., Caraco Y., Williams-Diaz A., Brown M.L., et al. Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients. N. Engl. J. Med. 2022;386:509–520. doi: 10.1056/NEJMoa2116044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2116044</ArticleId><ArticleId IdType="pmc">PMC8693688</ArticleId><ArticleId IdType="pubmed">34914868</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID-19 Treatment Guidelines Panel  Coronavirus Disease 2019 (COVID-19) Treatment Guidelines.  [(accessed on 26 October 2023)];2023  Available online:  https://www.covid19treatmentguidelines.nih.gov/</Citation></Reference><Reference><Citation>Tarke A., Sidney J., Methot N., Yu E.D., Zhang Y., Dan J.M., Goodwin B., Rubiro P., Sutherland A., Wang E., et al. Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals. Cell Rep. Med. 2021;2:100355. doi: 10.1016/j.xcrm.2021.100355.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2021.100355</ArticleId><ArticleId IdType="pmc">PMC8249675</ArticleId><ArticleId IdType="pubmed">34230917</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi S.J., Kim D.U., Noh J.Y., Kim S., Park S.H., Jeong H.W., Shin E.-C. T cell epitopes in SARS-CoV-2 proteins are substantially conserved in the Omicron variant. Cell Mol. Immunol. 2022;19:447–448. doi: 10.1038/s41423-022-00838-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-022-00838-5</ArticleId><ArticleId IdType="pmc">PMC8764507</ArticleId><ArticleId IdType="pubmed">35043006</ArticleId></ArticleIdList></Reference><Reference><Citation>Mallajosyula V., Ganjavi C., Chakraborty S., McSween A.M., Pavlovitch-Bedzyk A.J., Wilhelmy J., Nau A., Manohar M., Nadeau K.C., Davis M.M. CD8+ T cells specific for conserved coronavirus epitopes correlate with milder disease in COVID-19 patients. Sci. Immunol. 2021;6:eabg5669. doi: 10.1126/sciimmunol.abg5669.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abg5669</ArticleId><ArticleId IdType="pmc">PMC8975171</ArticleId><ArticleId IdType="pubmed">34210785</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertoletti A., Le Bert N., Qui M., Tan A.T. SARS-CoV-2-specific T cells in infection and vaccination. Cell Mol. Immunol. 2021;18:2307–2312. doi: 10.1038/s41423-021-00743-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-021-00743-3</ArticleId><ArticleId IdType="pmc">PMC8408362</ArticleId><ArticleId IdType="pubmed">34471260</ArticleId></ArticleIdList></Reference><Reference><Citation>Geers D., Shamier M.C., Bogers S., den Hartog G., Gommers L., Nieuwkoop N.N., Schmitz K.S., Rijsbergen L.C., van Osch J.A.T., Dijkhuizen E., et al. SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccinees recipients. Sci. Immunol. 2021;6:eabj1750. doi: 10.1126/sciimmunol.abj1750.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abj1750</ArticleId><ArticleId IdType="pmc">PMC9268159</ArticleId><ArticleId IdType="pubmed">34035118</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo L., Wang G., Wang Y., Zhang Q., Ren L., Gu X., Huang T., Zhong J., Wang Y., Wang X., et al. SARS-CoV-2-specific antibody and T-cell responses 1 year after infection in people recovered from COVID-19: A longitudinal cohort study. Lancet Microbe. 2022;3:e348–e356. doi: 10.1016/S2666-5247(22)00036-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-5247(22)00036-2</ArticleId><ArticleId IdType="pmc">PMC8942480</ArticleId><ArticleId IdType="pubmed">35345417</ArticleId></ArticleIdList></Reference><Reference><Citation>Marcotte H., Piralla A., Zuo F., Du L., Cassaniti I., Wan H., Kumagai-Braesh M., Andréll J., Percivalle E., Sammartino J.C., et al. Immunity to SARS-CoV-2 up to 15 months after infection. iScience. 2022;25:103743. doi: 10.1016/j.isci.2022.103743.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2022.103743</ArticleId><ArticleId IdType="pmc">PMC8736281</ArticleId><ArticleId IdType="pubmed">35018336</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherina N., Piralla A., Du L., Wan H., Kumagai-Braesch M., Andréll J., Braesch-Andersen S., Cassaniti I., Percivalle E., Sarasini A., et al. Persistence of SARS-CoV-2-specific B and T cell responses in convalescent COVID-19 patients 6-8 months after the infection. Med. 2021;2:281–295.e4. doi: 10.1016/j.medj.2021.02.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.medj.2021.02.001</ArticleId><ArticleId IdType="pmc">PMC7874960</ArticleId><ArticleId IdType="pubmed">33589885</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung J.H., Rha M.S., Sa M., Choi H.K., Jeon J.H., Seok H., Park D.W., Park S.-H., Jeong H.W., Choi W.S., et al. SARS-CoV-2-specific T cell memory is sustained in COVID-19 convalescent patients for 10 months with successful development of stem cell-like memory T cells. Nat. Commun. 2021;12:4043. doi: 10.1038/s41467-021-24377-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-24377-1</ArticleId><ArticleId IdType="pmc">PMC8245549</ArticleId><ArticleId IdType="pubmed">34193870</ArticleId></ArticleIdList></Reference><Reference><Citation>Ni L., Cheng M.L., Feng Y., Zhao H., Liu J., Ye F., Ye Q., Zhu G., Li X., Wang P., et al. Impaired cellular immunity to SARS-CoV-2 in severe COVID-19 patients. Front. Immunol. 2021;12:603563. doi: 10.3389/fimmu.2021.603563.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.603563</ArticleId><ArticleId IdType="pmc">PMC7884325</ArticleId><ArticleId IdType="pubmed">33603759</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergamaschi L., Mescia F., Turner L., Hanson A.L., Kotagiri P., Dunmore B.J., Ruffieux H., De Sa A., Huhn O., Morgan M.D., et al. Longitudinal analysis reveals that delayed bystander CD8+ T cell activation and early immune pathology distinguish severe COVID-19 from mild disease. Immunity. 2021;54:1257–1275.e8. doi: 10.1016/j.immuni.2021.05.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2021.05.010</ArticleId><ArticleId IdType="pmc">PMC8125900</ArticleId><ArticleId IdType="pubmed">34051148</ArticleId></ArticleIdList></Reference><Reference><Citation>Papayanni P.G., Chasiotis D., Koukoulias K., Georgakopoulou A., Iatrou A., Gavriilaki E., Giannaki C., Bitzani M., Geka E., Tasioudis P., et al. Vaccinated and convalescent donor-derived severe acute respiratory syndrome coronavirus 2-specific T cells as adoptive immunotherapy for high-risk coronavirus disease 2019 patients. Clin. Infect. Dis. 2021;73:2073–2082. doi: 10.1093/cid/ciab371.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab371</ArticleId><ArticleId IdType="pmc">PMC8135332</ArticleId><ArticleId IdType="pubmed">33905481</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreras C., Pascual-Miguel B., Mestre-Durán C., Navarro-Zapata A., Clares-Villa L., Martín-Cortázar C., De Paz R., Marcos A., Vicario J.L., Balas A., et al. SARS-CoV-2-specific memory T lymphocytes from COVID-19 convalescent donors: Identification, biobanking, and large-scale production for adoptive cell therapy. Front. Cell Dev. Biol. 2021;9:620730. doi: 10.3389/fcell.2021.620730.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcell.2021.620730</ArticleId><ArticleId IdType="pmc">PMC7947351</ArticleId><ArticleId IdType="pubmed">33718360</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper R.S., Fraser A.R., Smith L., Burgoyne P., Imlach S.N., Jarvis L.M., Turner D.M., Zahra S., Turner M.L., Campbell J.D.M. Rapid GMP-compliant expansion of SARS-CoV-2-specific T cells from convalescent donors for use as an allogeneic cell therapy for COVID-19. Front. Immunol. 2020;11:598402. doi: 10.3389/fimmu.2020.598402.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.598402</ArticleId><ArticleId IdType="pmc">PMC7819874</ArticleId><ArticleId IdType="pubmed">33488592</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim N., Lee J.M., Oh E.J., Jekarl D.W., Lee D.G., Im K.I., Cho S.-G. Off-the-shelf partial HLA matching SARS-CoV-2 antigen specific T cell therapy: A new possibility for COVID-19 treatment. Front. Immunol. 2021;12:751869. doi: 10.3389/fimmu.2021.751869.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.751869</ArticleId><ArticleId IdType="pmc">PMC8733616</ArticleId><ArticleId IdType="pubmed">35003063</ArticleId></ArticleIdList></Reference><Reference><Citation>Papadopoulou A., Karavalakis G., Papadopoulou E., Xochelli A., Bousiou Z., Vogiatzoglou A., Papayanni P.-G., Georgakopoulou A., Giannaki M., Stavridou F., et al. SARS-CoV-2-specific T cell therapy for severe COVID-19: A randomized phase 1/2 trial. Nat. Med. 2023;29:2019–2029. doi: 10.1038/s41591-023-02480-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-023-02480-8</ArticleId><ArticleId IdType="pubmed">37460756</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie X., Liu Y., Liu J., Zhang X., Zou J., Fontes-Garfias C.R., Xia H., Swanson K.A., Cutler M., Cooper D., et al. Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera. Nat. Med. 2021;27:620–621. doi: 10.1038/s41591-021-01270-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01270-4</ArticleId><ArticleId IdType="pubmed">33558724</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasileiou S., Hill L., Kuvalekar M., Workineh A.G., Watanabe A., Velazquez Y., Lulla S., Mooney K., Lapteva N., Grilley B.J., et al. Allogeneic, off-the-shelf, SARS-CoV-2-specific T cells (ALVR109) for the treatment of COVID-19 in high-risk patients. Haematologica. 2023;108:1840–1850. doi: 10.3324/haematol.2022.281946.</Citation><ArticleIdList><ArticleId IdType="doi">10.3324/haematol.2022.281946</ArticleId><ArticleId IdType="pmc">PMC10316279</ArticleId><ArticleId IdType="pubmed">36373249</ArticleId></ArticleIdList></Reference><Reference><Citation>Panikkar A., Lineburg K.E., Raju J., Chew K.Y., Ambalathingal G.R., Rehan S., Swaminathan S., Crooks P., Le Texier L., Beagley L., et al. SARS-CoV-2-specific T cells generated for adoptive immunotherapy are capable of recognizing multiple SARS-CoV-2 variants. PLoS Pathog. 2022;18:e1010339. doi: 10.1371/journal.ppat.1010339.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1010339</ArticleId><ArticleId IdType="pmc">PMC8880869</ArticleId><ArticleId IdType="pubmed">35157735</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu B., Guo H., Zhou P., Shi Z.L. Characteristics of SARS-CoV-2 and COVID-19. Nat. Rev. Microbiol. 2021;19:141–154. doi: 10.1038/s41579-020-00459-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-020-00459-7</ArticleId><ArticleId IdType="pmc">PMC7537588</ArticleId><ArticleId IdType="pubmed">33024307</ArticleId></ArticleIdList></Reference><Reference><Citation>Lam B., Kung Y.J., Lin J., Tseng S.H., Tsai Y.C., He L., Castiglione G., Egbert E., Duh E.J., Bloch E.M., et al. In vivo characterization of emerging SARS-CoV-2 variant infectivity and human antibody escape potential. Cell Rep. 2021;37:109838. doi: 10.1016/j.celrep.2021.109838.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2021.109838</ArticleId><ArticleId IdType="pmc">PMC8491932</ArticleId><ArticleId IdType="pubmed">34648735</ArticleId></ArticleIdList></Reference><Reference><Citation>Israelow B., Song E., Mao T., Lu P., Meir A., Liu F., Alfajaro M.M., Wei J., Dong H., Homer R.J., et al. Mouse model of SARS-CoV-2 reveals inflammatory role of type I interferon signaling. J. Exp. Med. 2020;217:e20201241. doi: 10.1084/jem.20201241.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20201241</ArticleId><ArticleId IdType="pmc">PMC7401025</ArticleId><ArticleId IdType="pubmed">32750141</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang M.S., Park M.J., Lee J., Oh B., Kang K.W., Kim Y., Lee S.-M., Lim J.-O., Jung T.-Y., Park J.-H., et al. Non-invasive administration of AAV to target lung parenchymal cells and develop SARS-CoV-2-susceptible mice. Mol. Ther. 2022;30:1994–2004. doi: 10.1016/j.ymthe.2022.01.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2022.01.010</ArticleId><ArticleId IdType="pmc">PMC8739362</ArticleId><ArticleId IdType="pubmed">35007757</ArticleId></ArticleIdList></Reference><Reference><Citation>Sefik E., Israelow B., Mirza H., Zhao J., Qu R., Kaffe E., Song E., Halene S., Meffre E., Kluger Y., et al. A humanized mouse model of chronic COVID-19. Nat. Biotechnol. 2022;40:906–920. doi: 10.1038/s41587-021-01155-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41587-021-01155-4</ArticleId><ArticleId IdType="pmc">PMC9203605</ArticleId><ArticleId IdType="pubmed">34921308</ArticleId></ArticleIdList></Reference><Reference><Citation>Min G.J., Kim H.J., Kim T.G., Hyun Y.S., Hyun S.J., Baek I.C., Yoon S.Y., Park S., Park S., Yoon J., et al. Specific donor HLA allotypes as predictors of cytomegalovirus disease risk in acute myeloid leukemia. HLA. 2020;96:445–455. doi: 10.1111/tan.13966.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/tan.13966</ArticleId><ArticleId IdType="pubmed">32506817</ArticleId></ArticleIdList></Reference><Reference><Citation>Höppner M., Luhm J., Schlenke P., Koritke P., Frohn C. A flow-cytometry based cytotoxicity assay using stained effector cells in combination with native target cells. J. Immunol. Methods. 2002;267:157–163. doi: 10.1016/S0022-1759(02)00167-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-1759(02)00167-9</ArticleId><ArticleId IdType="pubmed">12165437</ArticleId></ArticleIdList></Reference><Reference><Citation>Jang W.D., Jeon S., Kim S., Lee S.Y. Drugs repurposed for COVID-19 by virtual screening of 6,218 drugs and cell-based assay. Proc. Natl. Acad. Sci. USA. 2021;118:e2024302118. doi: 10.1073/pnas.2024302118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2024302118</ArticleId><ArticleId IdType="pmc">PMC8325362</ArticleId><ArticleId IdType="pubmed">34234012</ArticleId></ArticleIdList></Reference><Reference><Citation>Vita R., Mahajan S., Overton J.A., Dhanda S.K., Martini S., Cantrell J.R., Wheeler D.K., Sette A., Peters B. The Immune Epitope Database (IEDB): 2018 update. Nucleic Acids Res. 2019;47:D339–D343. doi: 10.1093/nar/gky1006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gky1006</ArticleId><ArticleId IdType="pmc">PMC6324067</ArticleId><ArticleId IdType="pubmed">30357391</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>